Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Oct
31
Today In Oncology
OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
Selpercatinib Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes
ASTRO Updates Guideline on Shorter-Course Radiation Therapy for Localized Prostate Cancer
High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo